The FDA issued a complete response letter for the BLA submission of subcutaneous amivantamab for EGFR-mutated NSCLC, citing ...

With the Oncology Brothers, Uma Borate, MD, discusses how CPX-351 demonstrates superior efficacy over 7+3 chemotherapy in ...

Ensartinib has received FDA approval for the first-line treatment of anaplastic lymphoma kinase (ALK)-positive locally ...

During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed ...

In an interview with Targeted Oncology, Jaime Merchan, MD, delved into data from the LITESPARK-013 trial evaluating ...

Following a complete response letter and biologics license application resubmission, the FDA has approved remestemcel-L for ...

Alexa Simon Meara, MD, discusses the importance of including a rheumatology approach to immunotherapy treatment for cancer.

Frontline tyrosine kinase inhibitors are well-established for chronic myelogenous leukemia, but some patients experience inadequate response or adverse events, highlighting the need for novel ...

Panelists discuss how the NCCN Guidelines define lower-risk myelodysplastic syndrome (LR-MDS) based on clinical hallmarks such as anemia and cytopenias, with treatment decisions guided by prognostic ...

Panelists discuss how frontline luspatercept is emerging as an effective treatment for anemia in lower-risk myelodysplastic syndrome (LR-MDS), demonstrating significant improvements in hemoglobin ...

With the Oncology Brothers, Uma Borate, MD, discusses how the combination of venetoclax with an IDH1 inhibitor and 7+3 ...

Panelists discuss how recent therapeutic advances, including novel drug combinations and personalized treatment approaches, ...